期刊文献+

提高人肺腺癌裸鼠皮下移植瘤成瘤率的方法学研究 被引量:5

Methodological study on improving tumor formation rate of xenografted human lung cancer in nude mice
暂未订购
导出
摘要 目的:提高人肺腺癌裸鼠皮下移植瘤的成瘤率。方法:人肺腺癌SPC-A-1、GLC-82培养细胞或相应的瘤组织匀浆接种于裸鼠皮下之前,先用富含生长因子的小鼠肉瘤S180腹水上清液按比例稀释,然后在裸鼠背部或腋窝皮下接种。观察人肿瘤细胞或肿瘤组织在加入小鼠肉瘤S180腹水上清液后,对移植瘤生长速度及成瘤率的影响。结果:加入小鼠肉瘤S180腹水上清液后,人肺腺癌SPC-A-1和GLC-82成瘤率明显提高,而且移植后的人肿瘤生长速度较未加小鼠肉瘤S180腹水上清液的人肺腺癌细胞明显加快。结论:小鼠肉瘤S180腹水上清液能明显提高人肺腺癌SPC-A-1和GLC-82裸鼠皮下移植瘤的成瘤率,促进肿瘤生长。 AIM:To improve tumor formation rate of xenografted human lung cancer in nude mice.METHODS:Before xenograftion,human lung cancer SPC-A-1 or GLC-82 cells and their tissue homogenate were diluted with supernatant of mice sarcoma 180 ascites being rich in growth factors.The diluted SPC-A-1 or GLC-82 cell suspensions were injected subcutaneously at right back or armpit of nude mice.The effects of supernatant of mice sarcoma 180 ascites on the tumor growth rate and tumor formation rate were evaluated.RESULTS:Compared with control group,the tumor growth rate and tumor formation rate of human lung cancer SPC-A-1 or GLC-82 in nude mice were significantly improved with the addition of the supernatant of mice sarcoma 180 ascites.CONCLUSION:The supernatant of mice sarcoma 180 ascites can significantly improve the tumor growth rate and tumor formation rate of human lung cancer SPC-A-1 or GLC-82 in nude mice.
出处 《中国临床药理学与治疗学》 CAS CSCD 2007年第9期1052-1057,共6页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 人肺癌 裸小鼠 肿瘤模型 抑制率 human lung cancer nude mice tumor model inhibition rate
  • 相关文献

参考文献17

二级参考文献36

  • 1李文锦,钱和年.人卵巢上皮性癌裸鼠皮下移植瘤模型和腹水瘤模型的建立[J].中华妇产科杂志,1993,28(1):38-40. 被引量:21
  • 2[1]Barinaga M. Designing therapies that target tumor blood vessels[J]. Science, 1997, 275 (5299): 482-484.
  • 3[2]Yoshikawa T,Tsuburaya A,Kobayashi O, et al. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma[J]. Cancer Lett, 2000, 153 (1-2) : 7-12.
  • 4[3]Miyake H, Hara I, Yamanaka K, et al. Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer[J]. Urology, 1999, 53 (2): 302-307.
  • 5[4]Chen CA, Cheng WF, Lee CN, et al. Serum vascular endothelial growth factor in epithelial ovarian neoplasma correlation with patient survival[J]. Gynecol Oncol, 1999, 74 (2): 235-240.
  • 6[5]Brattstrom D,Bergqvist M,Larsson A, et al. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients[J]. Anticancer Res, 1998, 18 (2A):1123-1127.
  • 7[6]Abendstein B,Daxenbichler G,Windbichcer G, et al. Predictive value of uPA, PAI-I, HER-2 and VEGF in the serum of ovarian cancer patients[J]. Anticancer Res, 2000, 20 (11B): 509-572.
  • 8[7]Freeman MR, Schneck FX, Gagnon ML, et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancer express vascular endothelial growth factor: A potential role for T cells in angiogenesis[J]. Cancer Res, 1995, 55 (18): 4140-4145.
  • 9[8]Mohle R, Green D, Moore MA, et al. Costitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets[J]. Proc Natl Acad Sci USA, 1997, 94 (2): 663-668.
  • 10[9]Webb NJ, Myers CR, Watson CJ, et al. Activated human neutrophils express vascular endothelial growth factor (VEGF)[J]. Cytolines, 1998, 10 (4): 254-257.

共引文献36

同被引文献52

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部